Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer disease
Cecchetti, G.; Agosta, F.; Rugarli, G.; Spinelli, E. G.; Ghirelli, A.; Zavarella, M.; Bottale, I.; Orlandi, F.; Santangelo, R.; Caso, F.; Magnani, G.; Filippi, M.
Show abstract
INTRODUCTIONConsiderable advancements have occurred in blood-based Alzheimers disease (AD) biomarkers, with automated assays emerging for clinical use. Demonstrating the reliability of these automated systems is crucial with upcoming AD therapies. METHODSThis cross-sectional study in a Memory Center enrolled 98 patients along the AD continuum or affected by other neurodegenerative disorders, stratified by CSF A/T status and clinical syndrome. Plasma pTau-217, pTau-181, and A{beta}42/A{beta}40 were measured using Lumipulse. Relationships with CSF and glomerular filtration rate (GFR) were explored. ROC analysis was conducted to assess diagnostic performance. RESULTSGFR effect was lowered by the use of ratios and pTau-217 correlation with CSF was strong. Plasma pTau-217 discriminated A+/T+ status with excellent accuracy in both dementia and mild cognitive impairment (AUC 0.93-0.97), outperforming pTau-181 and A{beta}42/A{beta}40. Cutoffs displayed high diagnostic performance. DISCUSSIONLumipulse automated pTau-217 and identified cutoffs exhibit excellent diagnostic accuracy for CSF A+/T+ status and clinical group detection, facilitating future clinical translation.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort 98%
- Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease 98%
- Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer’s Disease patients and cognitively normal individuals 96%
Similar papers in this journal
- Differences between plasma and CSF p-tau181 and p-tau231 in early Alzheimer’s disease 99%
- The Association of Alzheimer’s Disease-related Blood-based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa 98%
- CSF sphingomyelins in Alzheimer’s disease, neurodegeneration, and neuroinflammation 96%
Similar papers in this journal
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 97%
- Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum 97%
- CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status 96%
Similar papers in this journal
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 97%
- Identifying Proteomic Prognostic Markers for Alzheimer’s Disease with Survival Machine Learning: the Framingham Heart Study 96%
- Plasma brain-derived p-tau217 outperforms other p-tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden 95%